• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHOU Changkai,YU Hongxia,CAO Mingchen,SHI Yunyan,LIU Donghua,JI Hongyan,XING Xiaomin,WANG Xinyi,LI Jing,JING Fanbo.CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants: interpretation of the 2023 CPIC guideline[J].Journal Of Pharmaceutical Research,2024,43(5):495-503[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2990times   Download 2725次 QR Code for this article
Scan with your phone!
CYP2D6、CYP2C19、CYP2B6、SLC6A4、HTR2A基因型和5-羟色胺再摄取抑制剂抗抑郁药:2023年CPIC指南解读
周长凯,于红霞,曹铭晨,史云燕,刘东华,纪洪艳,邢晓敏,王心怡,李静,荆凡波
Font:Larger+|Default|Smaller-
(青岛大学附属医院药学部,山东 青岛 266100)
摘要:
2023年临床药物基因组学实施联盟(CPIC)更新并扩展了2015年CYP2D6和CYP2C19基因型与选择性5-羟色胺再摄取抑制物(SSRIs)治疗指南。在涉及基因型与药物部分分别增加了CYP2B6、5-羟色胺转运体SLC6A4、5-羟色胺2A受体HTR2A基因与5-羟色胺和去甲肾上腺素再摄取抑制剂(SNRIs)、类SSRIs活性的5-羟色胺(5-HT)调节剂相关内容,并更新了基于基因多态性的5-HT再摄取抑制剂类药物应用建议。本文对该指南的相关内容进行解读,以期为我国5-HT再摄取抑制剂类药物个体化治疗管理提供参考。
关键词:  指南  基因多态性  5-羟色胺再摄取抑制剂  抗抑郁药  解读
DOI:10.13506/j.cnki.jpr.2024.05.014
基金项目:山东省自然科学基金(No.ZR2022MH069);山东省医务职工科技创新计划项目(No.SDYWZGKCJH2023095);山东省医学会临床药学科研专项(No.YXH2021ZX010)
Publication Date:May 25, 2024
CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants: interpretation of the 2023 CPIC guideline
ZHOU Changkai,YU Hongxia,CAO Mingchen,SHI Yunyan,LIU Donghua,JI Hongyan,XING Xiaomin,WANG Xinyi,LI Jing,JING Fanbo
(Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao 266100, China)
Abstract:
The Clinical Pharmacogenetics Implementation Consortium (CPIC) updated and expanded the 2015 guideline for CYP2D6 and CYP2C19 genotypes and selective serotonin reuptake inhibitors (SSRIs) in July 2023, adding CYP2B6, SLC6A4, HTR2A, SNRIs, and 5-HT modulators with SSRI-like activity in the sections related to genotype and drugs. The new guideline also updated the application recommendations for serotonin reuptake inhibitors based on gene polymorphism. This article interprets the relevant content of the guideline, in order to provide reference for the individualized treatment of 5-HT reuptake inhibitors in China.
Key words:  Guideline  Genetic polymorphism  Serotonin reuptake inhibitor  Interpretation
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.